刘肖肖

刘肖肖drliuxx@126.com

刘肖肖，出生于1991年，汉族，医学博士，现任徐州医科大学附属医院肿瘤放疗科副主任医师、副教授、硕士生导师。2017年毕业于四川大学华西临床医学院（八年制）。入选江苏省“双创博士”、省“333工程”培养对象及U35青年科技新锐。长期致力于肿瘤免疫与靶向治疗的基础研究、临床转化及精准诊疗探索。主持国家自然科学基金（面上项目、青年项目）、中央引导地方科技发展专项、江苏省自然科学基金等课题10余项。以第一或通讯作者（含共同）在STTT（3篇）、ACS Central Science、Theranostics、MedComm（2篇）、Molecular Biomedicine（2篇）等期刊发表系列原创论文。获授权发明专利1项，荣获江苏省研究型医院学会医学青年奖。参与多中心临床研究20余项，作为主要研究者发起IIT研究5项，累计入组近500例；相关成果以口头报告或壁报形式在SABCS、ASCO、ESMO等国际顶级学术会议展示。

主要研究方向：

（1）肿瘤免疫靶向递送系统开发及双效协同干预策略；

（2）乳腺癌靶向联合免疫治疗的协同增效机制研究及前瞻性临床转化体系构建。

联系方式：drliuxx@126.com

代表性论文：

（1）Haoran Hu, Tao Han, Qiyuan Huang, Ping Gong, Jiangxi Liu, Hao Wang, Xiaowei Ling, Kang Wang, Shuangshuang Liu, Yue Yu, Ting Luo, Feng Cheng,Xiaoxiao Liu(通讯作者). Solute Carrier Family 1 Member 5 (SLC1A5)-dependent glutamine transport regulates macrophage senescence and efferocytosis during liver regeneration.Molecular Biomedicine. 2026, 7, 155.

（2）Xie Xin, Li Juanjuan, Zhang Aaron Qi, Wu Liang, Wu Chao, Patrick Ming-Kuen Tang,Liu Xiaoxiao(通讯作者). FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinom.Discover Oncology. 2026, 17(1):465.

（3）Liu Xiaoxiao(第一兼并通), Zhuang Chunying, Liu Lei, Xiong Ling, Xie Xin, He Ping, Li Juanjuan, Wei Bing, Yan Xi, Tian Tinglun, Zhong Xiaorong, Chen Jie, Cheng Yan, Zheng Dan, Cheng Peng, Sun Tianlin, Li Weiwei, Zhu Changbin, Chen Shuaitong, Fang Chao, Fu Jun, Li Shibao, Jing Jing, Luo Ting. Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis.Signal Transduction and Targeted Therapy. 2025, 10(1):237.

（4）Liu Xiaoxiao(第一作者), Zhang Xing, Shao Zhiying, Zhong Xiaorong, Ding Xin, Wu Liang, Chen Jie, He Ping, Cheng Yan, Zhu Kunrui, Zheng Dan, Jing Jing, Luo Ting. Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer.Signal Transduction and Targeted Therapy. 2023, 8: 463.

（5）Hu Yuzhu,Liu Xiaoxiao (共同一作), Ran Mengni, Yang Tingting, Li Tingting, Wu Yin, Lin Yunfeng, Qian Zhiyong, Gao Xiang. Simultaneous delivery of immune stimulatory gene and checkpoint blocker via targeted anoparticles to strengthen antitumor immunity.Materials Today Nano. 2022, 17: 1-15.

（6）Liu Xiaoxiao(第一作者), Ting Yu, Yuzhu Hu, Longzhen Zhang, Junnian Zheng, Xiawei Wei. The molecular mechanism of acute liver injury and inflammatory response induced by Concanavalin A.Molecular Biomedicine.2021, 2(24): 1-12.

（7）Liu Xiaoxiao(第一作者), Xin Xie, Yuanyuan Ren, Zhiying Shao, Nie Zhang, Liantao Li, Xin Ding, Longzhen Zhang. The role of necroptosis in disease and treatment.MedComm.2021, 2(4):730-755.

（8）Liu Xiaoxiao(第一作者), Wang Bilan, Li Yanyan, Hu Yuzhu, Li Xiaoling, Yu Ting, Ju Yan, Sun Tao, Gao Xiang, Wei Yuquan. Powerful Anticolon Tumor Effect of Targeted Gene Immunotherapy Using Folate-Modified Nanoparticle Delivery of CCL19 To Activate the Immune System.ACS central science. 2019, 5(2): 277-289.

（9）Liu Xiaoxiao(第一作者), Li Yanyan, Sun Xiaodong, MuftuogluYagmur, Wang Bilan, Yu Ting, Hu Yuzhu, Ma Lu, Xiang Mingli, Guo Gang, You Chao, Gao Xiang, Wei Yuquan. Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system.Theranostics. 2018, 8(13): 3490-3503.

（10）Liu Xiaoxiao(第一作者), Gao Xiang, Zheng Songping, Wang Bilan, Li Yanyan, Zhao Chanjuan, Muftuoglu Yagmur, Chen Song, Li Ying, Yao Haiyan, Sun Hui, Mao Qing, You Chao, Guo Gang, Wei Yuquan. Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer.NANOMED-NANOTECHNOL. 2017, 13(6): 1993-2004